after surgery, significantly declines until day 2 and continues to decline over the following months until pre-operative values are restored. 28 The protein content of the aqueous humour has been considered to arise mainly in the anterior chamber, leading to the hypothesis that dilution of aqueous in the anterior chamber may be the mechanism by which pupil dilation decreases aqueous flare.
29
Cooled intraocular irrigation reduces post-operative BAB disturbance after cataract surgery, but this effect is short-lived and may even prolong disturbance of BAB at a low intensity. 27 Various studies have reported reduction in aqueous flare following the application of tropicamide in normal patients, but only one study of the effect of mydriasis on aqueous flare in pseudophakic patients reported a decrease of 20% after three hours with a tropicamide and phenylephrine solution. 30 However, the relative reduction in flare after tropicamide pupil dilation in the pseudophakic eye has been shown to be similar to the reduction before surgery, making it unlikely that the decrease in flare after pupil dilation is a consequence of the dilution. Several factors contribute to the issues of treatment protocols for postoperative ocular inflammation. For example, cataract surgery is a procedure that occurs mostly in elderly patients, a population in which compliance to medication is known to be poor. A treatment with eyedrops that have to be applied several times a day already presents a compliance problem, but can be particularly off-putting when associated with side effects such as stinging and burning, as is the case with eye drops for post-operative inflammation. A good rate of persistence and compliance to ophthalmic NSAID treatment is likely to result in improved efficacy. A faster recovery to pre-operative conditions would be expected to result in an improvement in the patient's quality of life.
Key Characteristics of an Ideal Topical Ophthalmic NSAID and Currently Approved NSAIDs
Ophthalmic NSAIDs play several critical roles in cataract surgery.
Through their inhibition of PGs, they prevent intra-operative miosis, manage post-operative inflammation, prevent and treat CME, as well as reduce pain and discomfort following surgery (see Figure 1) . Redefining the Treatment Paradigm for Post-operative Inflammation Control Furthermore, although studies have found no significant differences between the efficacy of NSAIDs and corticosteroids, NSAIDs do appear to be more effective at rebuilding the BAB. The currently available topical ophthalmic NSAIDs have frequent dosing schedules (three-or four-times daily). There is evidence from several clinical studies, mainly in glaucoma patients, suggesting that improvements in patient compliance can be associated with less frequent dosing. 54-59 Therefore, it may be predicted that an NSAID with a less frequent dosing schedule could potentially offer improved patient compliance and persistence to treatment. It has also been suggested that reduced dosing schedules may reduce corneal epithelial toxicity since the patient's exposure to the drug and to potentially toxic preservatives would be reduced. 60 The twice-daily topical ophthalmic NSAID, bromfenac, is approved in 
The Pharmacokinetic Profile of the Bromfenac Ophthalmic Solution
Bromfenac is a derivative of amfenac that includes an additional bromonium ion. This enhances the lipophilicity of bromfenac, which in turn may facilitate penetration of the compound into all ocular tissues and thereby enhance the drug's potency. 12, 14, [61] [62] [63] [64] This pharmacokinetic profile will likely be the major contributing factor to the molecules' deep tissue penetration, early and sustained drug levels demonstrated in 
Clinical Efficacy and Safety of the Bromfenac Ophthalmic Solution
One of the first in vivo studies demonstrating the efficacy of topical bromfenac on ocular inflammation, performed in Japan, showed that bromfenac was almost 11 times more potent than pranoprofen at preventing the production of prostaglandins from rabbit iris ciliary body. 66 More recently, the pooled results of two large double-blinded, phase III trials have been reported. 26 In those trials, post-cataract surgery subjects who had moderate to severe signs of anterior segment inflammation at baseline were randomly assigned to either Table 2 ). In terms of ocular comfort, ocular events (including burning, stinging and eye irritation) were only mild and occurred less frequently in bromfenac-versus placebo-treated subjects. Importantly, the incidence of burning and stinging with bromfenac is one of the lowest versus the other available topical ophthalmic NSAIDs. [67] [68] [69] [70] proportion of subjects until day 14. 73 In another study, a statistically significant change from baseline in anterior chamber cell score was not observed until day 6, as reported for ketorolac. 74 In a prospective, randomised study, bromfenac was as effective as betamethasone in the treatment of post-operative inflammation after cataract surgery. 75 In the pivotal clinical studies bromfenac has shown some potential to reduce the risk of CME, with a reported 30% lower incidence of CME (1.4% in the active group versus 4.7% in the vehicle alone group).
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Less retinal thickening has also been shown in another study at four and six weeks after cataract surgery in patients with non-proliferative diabetic retinopathy. In clinical practice, an optimal ophthalmic NSAID therapy will have highly effective anti-inflammatory activity, a rapid onset of action that produces sustained relief of inflammation, a formulation that is comfortable and well tolerated, and a convenient dosing regimen. Based upon its features, bromfenac seems to satisfy these parameters.
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